Logo image of SPRB

SPRUCE BIOSCIENCES INC (SPRB) Stock Fundamental Analysis

NASDAQ:SPRB - Nasdaq - US85209E1091 - Common Stock - Currency: USD

0.1187  0 (-3.5%)

After market: 0.1139 0 (-4.04%)

Fundamental Rating

1

SPRB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of SPRB have multiple concerns. SPRB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SPRB has reported negative net income.
SPRB had a negative operating cash flow in the past year.
SPRB had negative earnings in each of the past 5 years.
In the past 5 years SPRB always reported negative operating cash flow.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of SPRB (-60.56%) is worse than 60.39% of its industry peers.
Looking at the Return On Equity, with a value of -76.35%, SPRB is in line with its industry, outperforming 54.05% of the companies in the same industry.
Industry RankSector Rank
ROA -60.56%
ROE -76.35%
ROIC N/A
ROA(3y)-44.49%
ROA(5y)-86.02%
ROE(3y)-56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

More info and screens

3

2. Health

2.1 Basic Checks

SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRB has been increased compared to 1 year ago.
Compared to 5 years ago, SPRB has more shares outstanding
Compared to 1 year ago, SPRB has an improved debt to assets ratio.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

SPRB has an Altman-Z score of -5.79. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.79, SPRB is not doing good in the industry: 62.68% of the companies in the same industry are doing better.
SPRB has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.01, SPRB perfoms like the industry average, outperforming 42.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -5.79
ROIC/WACCN/A
WACC11%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.36 indicates that SPRB has no problem at all paying its short term obligations.
With a Current ratio value of 5.36, SPRB perfoms like the industry average, outperforming 58.10% of the companies in the same industry.
A Quick Ratio of 5.36 indicates that SPRB has no problem at all paying its short term obligations.
SPRB has a Quick ratio (5.36) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.36
Quick Ratio 5.36
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

SPRB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
The Revenue has decreased by -1.38% in the past year.
EPS 1Y (TTM)36.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)-1.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.41%

3.2 Future

The Earnings Per Share is expected to grow by 3.48% on average over the next years.
The Revenue is expected to decrease by -21.84% on average over the next years. This is quite bad
EPS Next Y24.39%
EPS Next 2Y24.04%
EPS Next 3Y13.78%
EPS Next 5Y3.48%
Revenue Next Year-40.59%
Revenue Next 2Y-51.7%
Revenue Next 3Y-1.27%
Revenue Next 5Y-21.84%

3.3 Evolution

SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SPRB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

SPRB's earnings are expected to grow with 13.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.04%
EPS Next 3Y13.78%

More info and screens

0

5. Dividend

5.1 Amount

SPRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (4/17/2025, 8:00:02 PM)

After market: 0.1139 0 (-4.04%)

0.1187

0 (-3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-14 2025-04-14/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners43.66%
Inst Owner Change0%
Ins Owners11.57%
Ins Owner Change2.63%
Market Cap4.90M
Analysts50
Price Target1.87 (1475.4%)
Short Float %1.16%
Short Ratio1.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.04%
Min EPS beat(2)13.31%
Max EPS beat(2)32.77%
EPS beat(4)4
Avg EPS beat(4)22.56%
Min EPS beat(4)5.11%
Max EPS beat(4)39.07%
EPS beat(8)7
Avg EPS beat(8)16.48%
EPS beat(12)10
Avg EPS beat(12)14.24%
EPS beat(16)13
Avg EPS beat(16)13.53%
Revenue beat(2)1
Avg Revenue beat(2)-27.46%
Min Revenue beat(2)-60.5%
Max Revenue beat(2)5.57%
Revenue beat(4)3
Avg Revenue beat(4)29.19%
Min Revenue beat(4)-60.5%
Max Revenue beat(4)102.17%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5%
EPS NY rev (1m)0%
EPS NY rev (3m)0.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-38.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.69
P/FCF N/A
P/OCF N/A
P/B 0.09
P/tB 0.09
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.17
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.56%
ROE -76.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.49%
ROA(5y)-86.02%
ROE(3y)-56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.26%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.36
Quick Ratio 5.36
Altman-Z -5.79
F-Score4
WACC11%
ROIC/WACCN/A
Cap/Depr(3y)50.95%
Cap/Depr(5y)65.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y24.39%
EPS Next 2Y24.04%
EPS Next 3Y13.78%
EPS Next 5Y3.48%
Revenue 1Y (TTM)-1.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.41%
Revenue Next Year-40.59%
Revenue Next 2Y-51.7%
Revenue Next 3Y-1.27%
Revenue Next 5Y-21.84%
EBIT growth 1Y18.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.96%
OCF growth 3YN/A
OCF growth 5YN/A